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even for the growth and establishment of hepatology at
the respective national levels.
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Non-alcoholic fatty liver disease (NAFLD) is a dis-
ease on the increase in the Western world with vast clin-
ical implications. Patients with NAFLD are susceptible
to develop NASH and are at risk of complications when
undergoing a liver resection, particularly in living donor
liver transplantation procedures [1]. In this setting mod-
erate and severe steatosis are considered exclusion crite-
ria. Consequently, clinically representative animal
models yielding an adequate steatosis degree are imper-
ative to conduct mechanistic and interventional investi-
gations. Presently, most models are based on genetic or
dietary adaptations. With respect to the former, ob/ob
mice lacking the leptin gene and Zucker fa/fa rats lack-
ing the leptin receptor exhibit hyperphagia resulting in
obesity, insulin resistance, and steatosis. However, the
drawback of these models includes the dissimilar etiol-
ogy of steatosis induction vs. its clinical counterpart
(i.e., genes vs. diet). Moreover, experimental studies
show that liver regeneration in these models appears
to be impaired not due to steatosis per se, but due to
the leptin deﬁciency. A clinically representative model
for experimental steatosis would thus be of great value.
In 2004 Lieber et al. [2] introduced a model using a
liquid high-fat diet for the induction of NASH in Spra-
gue–Dawley rats, referred to as the Lieber–Decarli
(LDC) diet. Within 3 weeks the animals purportedly
developed panlobular steatosis with inﬂammatory foci,
in association with insulin resistance and increased he-
patic TNF-a levels and lipid peroxidation products,
i.e., clinical features of NASH. In a recent study pub-
lished in this Journal, Lieber et al. [3] used mediumchain triglycerides to prevent LDC diet-induced NASH.
In this letter we would like to address several irreproduc-
ibility issues regarding the LDC diet and its solid high-
fat equivalent.
We have attempted to set up the LDC model in Wis-
tar rats following the authors’ exact methodology [2].
However, after a 3-week LDC diet none of the livers
(n = 5) showed any histological evidence of steatosis
(Fig. 1A). Our ﬁndings were recently corroborated by
Akin et al. [4] in Sprague–Dawley rats, where only
20% developed 1–2% microvesicular steatosis after a 3-
week LDC diet (Fig. 1B). In both studies, animals had
gained signiﬁcantly less weight (98 and 76 g, respec-
tively) after 3 weeks than the animals in the original
study (173 g). Alternatively, we attempted to induce ste-
atosis with a solid high-fat diet in accordance with Sve-
gliati-Baroni et al. [5]. A 3-, 5-, and 7-week diet resulted
in a mean ± SD histological steatosis degree of 10 ± 5%,
5 ± 3%, and 10 ± 9%, respectively, in Wistar rats (n = 5/
group) and 14 ± 11%, 2 ± 1%, and 0%, respectively, in
Sprague–Dawley rats (n = 5/group).
Next, the reproducibility of the LDC diet was evalu-
ated against other studies referring to the LDC diet.
Using the ISI Web of Science database (accessed 01/
15/2008), 53 articles citing the original work were re-
trieved: 38 experimental studies, 9 reviews, 5 clinical
studies, and 1 editorial paper. Of the 38 experimental
studies, 6 articles (Fig. 1C) reported the use of the
LDC diet, of which 2 actually followed its original
experimental 3-week diet protocol; both by Lieber
et al. [3,6]. In another study by Lieber et al. [7] the diet
was employed during 3 and 6 weeks. Interestingly, histo-
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Fig. 1. Histology from our experiments and from Akin et al. (A and B,
respectively). No steatosis was found after 3 weeks LDC diet in both
experiments. A literature search using ISI web of science revealed 6
studies (C) reporting the use of the LDC diet for steatosis induction.
Histological examples of mild (D) and severe (E) steatosis after a 1-
and 5-week methionine–choline deﬁcient diet. N.Q.=not quantiﬁed.
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studies by Lieber et al. Yalniz et al. [8] used a solid high-
fat diet with the same fat composition for 4 weeks,
resulting in mild steatosis, whereas Wang et al. [9] em-
ployed the LDC diet for 6 weeks and observed mild
steatosis.
Thus, albeit frequently cited, the original LDC proto-
col for NASH induction is in fact sparsely employed. In-
stead, the LDC diet is either completely modiﬁed to
achieve a greater degree of steatosis or applied for long-
er time periods to induce mild steatosis. These ﬁndings
make the utility of liquid and solid high-fat diets for
NASH-related studies highly questionable. Further-
more, interventional studies [3] in this model are to be
interpreted with due caution. It is well known that mild
steatosis (0–33%), as was observed in the studies listed in
Fig. 1C, have no major clinical implications in contrast
to moderate (33–66%) or severe (>66%) steatosis.
Consequently, it is paramount to use experimental mod-
els that produce high degrees of histological steatosis in
order to adequately test therapeutic and nutritional re-
gimes or surgical interventions. Unfortunately, no re-
ports exist achieving clinically relevant high degrees of
steatosis with liquid or solid high-fat diets.
In the ﬁnal analysis, a reproducible and eﬀective
means is needed to induce clinically relevant NASH. A
suitable method comprises the methionine–choline-deﬁ-
cient (MCD) diet. This diet metabolically deprives the li-
ver from crucial components required for the synthesis
of very low density lipoprotein, which is responsible
for triglyceride export from the liver [1]. In contrast to
the LDC diet, the MCD diet is highly eﬃcient, resulting
in mild steatosis after 1–2 weeks (Fig. 1D), moderate ste-
atosis after 3 weeks, and severe steatosis after 5 weeks
(Fig. 1E). This model is also associated with inﬂamma-
tory foci as well as increased TNF-a and lipid peroxida-
tion levels. Most importantly, this model has been usedby many diﬀerent research groups, all reporting the
same degrees of histological steatosis, and has therefore
proven to be highly reproducible.
In conclusion, the diﬃculties with reproducing high-
fat steatosis models is underexposed in literature and
should be taken into account when performing experi-
mental NAFLD studies.
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